Quince Therapeutics, Inc. short interest in 2022
In 2022, Quince Therapeutics, Inc.'s disclosed short interest ran from 28.24% of shares outstanding on 14 Jan 2022 to 9.12% on 30 Dec 2022, a change of -19.12 percentage points. The year's high was 28.24% on 14 Jan 2022 and its low 9.12% on 30 Dec 2022, averaging 15.14% across 20 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 22.10 days on 14 Oct 2022. Full history: Quince Therapeutics, Inc..
Cite this page
By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2022 in figures
- Start of year
- 28.24% (14 Jan 2022)
- End of year
- 9.12% (30 Dec 2022)
- Change
- -19.12 pp
- High
- 28.24% (14 Jan 2022)
- Low
- 9.12% (30 Dec 2022)
- Average
- 15.14%
- Highest days to cover
- 22.10 (14 Oct 2022)
- SEC filings marked
- 7
Every report in 2022
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 14 Jan 2022 | 28.24% | 10.89 | |
| 31 Jan 2022 | 24.47% | 4.23 | |
| 15 Feb 2022 | 18.02% | 5.35 | results (8-K) |
| 28 Feb 2022 | 18.50% | 8.93 | |
| 15 Mar 2022 | 18.12% | 10.00 | 10-K filed |
| 31 Mar 2022 | 17.18% | 11.87 | |
| 14 Apr 2022 | 16.59% | 13.75 | |
| 29 Apr 2022 | 19.19% | 11.84 | |
| 13 May 2022 | 17.66% | 14.16 | 10-Q filed, results (8-K) |
| 31 May 2022 | 15.72% | 9.87 | |
| 15 Jun 2022 | 14.97% | 9.24 | |
| 30 Jun 2022 | 12.49% | 4.80 | |
| 15 Jul 2022 | 12.17% | 11.89 | |
| 29 Jul 2022 | 12.24% | 11.80 | |
| 14 Oct 2022 | 9.77% | 22.10 | results (8-K), 10-Q filed |
| 31 Oct 2022 | 10.02% | 17.25 | |
| 15 Nov 2022 | 9.34% | 11.33 | 10-Q filed |
| 30 Nov 2022 | 9.50% | 16.21 | |
| 15 Dec 2022 | 9.52% | 14.84 | |
| 30 Dec 2022 | 9.12% | 9.61 |
See also: Quince Therapeutics, Inc.'s full history · most shorted US stocks of 2022 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.